Document Detail

Effect of 24-week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene.
MedLine Citation:
PMID:  16222898     Owner:  NLM     Status:  MEDLINE    
The aim of the present study was to assess the effect of treatment with the angiotensin II receptor blocker telmisartan for 24 weeks on myocardial structure and function in patients with essential hypertension, and the relationship between this effect and the structural polymorphism of the angiotensin-converting enzyme (ACE) gene. Thirty-five patients with essential hypertension and left ventricular hypertrophy (LVH) without other associated morbidity were included in an open-label, non-comparative study. The patients were treated with telmisartan 40-80 mg once daily. In the final analysis, there were 29 patients who received the full course of treatment and were evaluated echocardiographically before and after treatment by the same blinded investigator, and myocardial structure and function were analysed. The myocardial mass of the left ventricle was determined in M-mode. Assessment of diastolic function of transmitral blood flow was performed using pulsed Doppler echocardiography. All patients were genotyped for insertion/deletion (I/D) polymorphism of the ACE gene. Telmisartan produced a significant reduction in left ventricular mass index from 140.4 +/- 48.6 to 128.7 +/- 40.6 g/m2 that was accompanied by an improvement in characteristics of diastolic function. The decrease in LVH was more significant in the ID genotype group than in the II and DD groups. Thus, prolonged treatment with telmisartan is accompanied by an improvement in myocardial structure, expressed as a reduction in left ventricular mass and function that is more marked in patients with ID genotype of the ACE gene.
A O Conrady; I O Kiselev; N I Usachev; A N Krutikov; O I Yakovleva; E V Polunicheva; O A Ovchinnikova; A V Panov
Related Documents :
18645048 - Inappropriate left ventricular mass in patients with primary aldosteronism.
20435318 - New precordial bipolar electrocardiographic leads for detecting left ventricular hypert...
16814128 - Microalbuminuria and cardiovascular risk assessment in primary hypertension: should thr...
7763068 - Cardiac effects of growth hormone in short normal children: results after four years of...
12379408 - Consequences of ptfe membrane used for prevention of re-entry injuries in rheumatic val...
20676278 - Toll-like receptors and myocardial ischemia/reperfusion, inflammation, and injury.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The Journal of international medical research     Volume:  33 Suppl 1     ISSN:  0300-0605     ISO Abbreviation:  J. Int. Med. Res.     Publication Date:  2005  
Date Detail:
Created Date:  2005-10-14     Completed Date:  2005-11-03     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  0346411     Medline TA:  J Int Med Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  30A-38A     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Benzimidazoles / therapeutic use*
Benzoates / therapeutic use*
Echocardiography, Doppler
Gene Deletion
Hypertension / drug therapy
Hypertrophy, Left Ventricular / drug therapy
Middle Aged
Myocardium / metabolism*,  pathology*
Peptidyl-Dipeptidase A / genetics*
Polymorphism, Genetic
Time Factors
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Benzimidazoles; 0/Benzoates; EC A; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Angiotensin II receptor blocker telmisartan: effect on blood pressure profile and left ventricular h...
Next Document:  Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/...